ADJUNTIVE ANTIBIOTICS — Competitive Intelligence Brief

ADJUNTIVE ANTIBIOTICS (ADJUNTIVE ANTIBIOTICS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy. Area: Infectious Disease.

marketed Antibiotic combination therapy Infectious Disease Small molecule

Target snapshot

ADJUNTIVE ANTIBIOTICS (ADJUNTIVE ANTIBIOTICS) — University of Valencia. Adjunctive antibiotics are antimicrobial agents used in combination with other treatments to enhance therapeutic efficacy and reduce microbial resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ADJUNTIVE ANTIBIOTICS TARGET	ADJUNTIVE ANTIBIOTICS	University of Valencia	marketed	Antibiotic combination therapy
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
Helicobacter pylori eradication	Helicobacter pylori eradication	National Cancer Center, Korea	marketed	Antibiotic combination therapy / Proton pump inhibitor-based regimen
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis
group-B : Levofloxacin triple therapy	group-B : Levofloxacin triple therapy	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	marketed	Fluoroquinolone antibiotic combination therapy	Bacterial DNA gyrase, topoisomerase IV
clarithromycin-based triple therapy	clarithromycin-based triple therapy	National Taiwan University Hospital	marketed	Macrolide antibiotic combination therapy	Bacterial 50S ribosome (clarithromycin component)
Standard bismuth quadruple	Standard bismuth quadruple	Xijing Hospital of Digestive Diseases	marketed	Antibiotic combination therapy / Bismuth-based anti-ulcer agent	Helicobacter pylori (bacterial pathogen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy class)

1. West Virginia University · 2 drugs in this class
2. Mackay Memorial Hospital · 1 drug in this class
3. Takeda · 1 drug in this class
4. University of Valencia · 1 drug in this class
5. mohamed bouchoucha · 1 drug in this class